Printer Friendly

Articles from M2 Pharma (October 23, 2018)

1-21 out of 21 article(s)
Title Author Type Words
Acupath Laboratories welcomes Hillel Kahane, MD as CMO and director. 135
Amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress. 492
AstraZeneca and Merck announce Lynparza trial shows 70% reduction in PFS ovarian cancer. 433
East River BioSolutions wins USD224,566 NIH SBIR Phase I grant. 233
Eiger BioPharmaceuticals plans to launch public offering of common stock. 188
Enterome SA and Takeda to co-develop and co-promote investigational drug candidate EB8018. 292
ESSA Pharma names Otello Stampacchia as new director. 172
Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors. 1006
Incyte Touts Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma. Clinical report 877
Ipsen Presents Real-World Pancreatic Cancer Data on Onivyde at the European Society for Medical Oncology 2018 Annual Congress. 854
Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients. 161
Medline signs three year lab distribution agreement with Premier. 152
New Three-Year Data for Tremfya Demonstrates Well Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis, According to Janssen. Clinical report 455
Novartis' phase II GEOMETRY mono-one trial of capmatinib indicates positive results. 137
Opdivo in Combination with Yervoy Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma, According to Bristol-Myers Squibb. 459
Opdivo Plus Low-Dose Yervoy Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer. 577
Phase III Lonsurf Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer, According to Servier and Taiho Oncology. 952
PinneyAssociates names new chief medical officer and new vice president. 223
Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer. 143
Teva Formalises North America Headquarters Move with Ceremony in Israel. 200
Vertex Pharmaceuticals (Europe) receives positive opinion from European watchdog for Kalydeco. 140

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters